Technical Analysis for CASI - CASI Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| 50 DMA Support | Bullish | 1.69% | |
| MACD Bullish Centerline Cross | Bullish | 1.69% | |
| Stochastic Reached Overbought | Strength | 1.69% | |
| Upper Bollinger Band Walk | Strength | 1.69% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 1 day ago |
| Down 2 % | 1 day ago |
| Down 1% | 2 days ago |
| Fell Below Upper Bollinger Band | 2 days ago |
| Gap Up Closed | 3 days ago |
Get this analysis on your stocks daily!
- Earnings date: 04/24/2024
CASI Pharmaceuticals, Inc. Description
CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company's lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Pharmaceutical Disease Solid Tumors Autoimmune Disease Cancer Treatment Treatment Of Cancer Ovarian Cancer Leukemia Multiple Myeloma Platinum Stage Pharmaceutical Advanced Solid Tumors Cyclacel Cell Cycle Pyrrolidines
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.4757 |
| 52 Week Low | 1.86 |
| Average Volume | 46,942 |
| 200-Day Moving Average | 4.10 |
| 50-Day Moving Average | 2.97 |
| 20-Day Moving Average | 2.67 |
| 10-Day Moving Average | 2.88 |
| Average True Range | 0.29 |
| RSI (14) | 63.37 |
| ADX | 23.01 |
| +DI | 28.13 |
| -DI | 22.86 |
| Chandelier Exit (Long, 3 ATRs) | 2.66 |
| Chandelier Exit (Short, 3 ATRs) | 3.02 |
| Upper Bollinger Bands | 3.31 |
| Lower Bollinger Band | 2.04 |
| Percent B (%b) | 0.99 |
| BandWidth | 47.31 |
| MACD Line | 0.04 |
| MACD Signal Line | -0.09 |
| MACD Histogram | 0.1368 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.50 | ||||
| Resistance 3 (R3) | 3.48 | 3.39 | 3.47 | ||
| Resistance 2 (R2) | 3.39 | 3.34 | 3.40 | 3.46 | |
| Resistance 1 (R1) | 3.35 | 3.31 | 3.37 | 3.37 | 3.45 |
| Pivot Point | 3.26 | 3.26 | 3.27 | 3.27 | 3.26 |
| Support 1 (S1) | 3.21 | 3.21 | 3.24 | 3.23 | 3.15 |
| Support 2 (S2) | 3.12 | 3.17 | 3.13 | 3.14 | |
| Support 3 (S3) | 3.08 | 3.12 | 3.13 | ||
| Support 4 (S4) | 3.10 |
